NY Times article on stage IVs with stats and singling out her2+ breast

"We are learning more and more as to how the tumors get around the her2 blockage (her3, Egfr, IGFR1, Muc4, truncated her2, etc)

and another article I posted from U of Michigan shows we are discovering how the "metastatic niche" awakens the slumbering cancer stem cells and encourages metastasis"

How soon can it be learned enough to help the patients?